<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04528095</url>
  </required_header>
  <id_info>
    <org_study_id>TRS-SMART</org_study_id>
    <nct_id>NCT04528095</nct_id>
  </id_info>
  <brief_title>SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia</brief_title>
  <official_title>Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project intends to take treatment-resistant schizophrenia as the research object and uses&#xD;
      sequential multiple assignment randomized trial(SMART) design to define the treatment&#xD;
      recommendations of different drug regimen for treatment resistant schizophrenia and to&#xD;
      determine the physical enhancement regimen for clozapine-resistant schizophrenia and to&#xD;
      explore targeted regulation scheme for ultra-resistant schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a sequential multiple-assignment RCT design of antipsychotic drugs, planning to&#xD;
      recruit 162 people with treatment-resistant schizophrenia followed for 12 months. The study&#xD;
      includes three treatment phases and a naturalistic follow-up phase. Participants who meet the&#xD;
      response criteria remain on that treatment for the duration of 12-month treatment. If the&#xD;
      participants fail the treatment or can't tolerant the side effects, the patient moves to the&#xD;
      next phase of the study to receive a new treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Change from baseline PANSS score at 12 weeks</time_frame>
    <description>25% or greater change in Positive and Negative Syndrome Scale (PANSS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks, 16 weeks,32 weeks</time_frame>
    <description>The Barnes Akathisia Scale (BAS) (0,14,higher scores mean a worse outcome),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks, 16 weeks,32 weeks</time_frame>
    <description>Simpson-Angus Extrapyramidal Side Effects Scale (SAS) (0,40,higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks, 16 weeks,32 weeks</time_frame>
    <description>Abnormal Involuntary Movement Scale (AIMS) (0,42,higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive assessments and social function</measure>
    <time_frame>baseline, 6 weeks, 3 months, 6 months, 9 months, 12 months</time_frame>
    <description>The University of California, San Diego (UCSD) Performance- based Skills Assessment-Brief (UPSA-B) (0,100,higher scores mean a better outcome) is used to evaluate the social function,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive assessments and social function</measure>
    <time_frame>baseline, 6 weeks, 3 months, 6 months, 9 months, 12 months</time_frame>
    <description>The MATRICS consensus cognitive battery (MCCB) has been widely used to evaluate cognitive deficits in schizophrenia patients(0%,100%,higher scores mean a better outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical assessements</measure>
    <time_frame>baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks, 16 weeks,32 weeks</time_frame>
    <description>PANSS (30,210,higher scores mean a worse outcome),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical assessements</measure>
    <time_frame>baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks, 16 weeks,32 weeks</time_frame>
    <description>Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPS) (0,32,higher scores mean a worse outcome),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical assessements</measure>
    <time_frame>baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks, 16 weeks,32 weeks</time_frame>
    <description>Calgary Depression Scale for Schizophrenia (CDSS) (0,27,higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical assessements</measure>
    <time_frame>baseline, 4 weeks, 8 weeks, 12 weeks, 14 weeks, 16 weeks,32 weeks</time_frame>
    <description>Clinical Global Impression Scale-Severity (CGI-S) (0,7,higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Treatment-resistant Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Clozapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clozapine 400 ~ 600mg/d or plasma concentration &gt;350ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clozapine+Amisulpride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clozapine 400 ~ 600mg/d or plasma concentration &gt;350ng/ml Amisulpride 200-800mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clozapine+Gingke biloba</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clozapine 400 ~ 600mg/d or plasma concentration &gt;350ng/ml Gingke biloba 120-360mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MECT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MECT:The treatment lasted for 4 months,16 times in total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MST:The treatment lasted for 4 months,16 times in total</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>Clozapine 400 ~ 600mg/d or plasma concentration &gt;350ng/ml Amisulpride 200-800mg/d Gingke biloba 120-360mg/d</description>
    <arm_group_label>Clozapine</arm_group_label>
    <arm_group_label>Clozapine+Amisulpride</arm_group_label>
    <arm_group_label>Clozapine+Gingke biloba</arm_group_label>
    <other_name>Clozapine+Amisulpride</other_name>
    <other_name>Clozapine+Gingke biloba</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MECT</intervention_name>
    <description>MECT:The treatment lasted for 4 months,16 times in total MST:The treatment lasted for 4 months,16 times in total</description>
    <arm_group_label>MECT</arm_group_label>
    <arm_group_label>MST</arm_group_label>
    <other_name>MST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DBS</intervention_name>
    <description>Two electrode emplacement groups (target nucleus accumbens and hippocampus respectively)</description>
    <arm_group_label>DBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. meet the DSM-5 diagnostic criteria for schizophrenia,&#xD;
&#xD;
          2. be 18-55 years of age,&#xD;
&#xD;
          3. treatment-resistant schizophrenia:no response to sufficient doses (400-600 mg/ day CPZ&#xD;
             equivalent) of at least two antipsychotics in the past 5 years,&#xD;
&#xD;
          4. Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with medical or psychiatric comorbidities and those who require concomitant&#xD;
             other medications are excluded.&#xD;
&#xD;
          2. Patients with contraindications to even one of the proposed treatment arms are&#xD;
             excluded.&#xD;
&#xD;
          3. Patients with risks such as extreme agitation, stupor or suicide are excluded.&#xD;
&#xD;
          4. Female patients with pregnancy or breast-feeding are also excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dengtang Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dengtang Liu, MD</last_name>
    <phone>18017311138</phone>
    <email>erliu110@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 12, 2020</study_first_submitted>
  <study_first_submitted_qc>August 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>August 22, 2020</last_update_submitted>
  <last_update_submitted_qc>August 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Treatment-resistant</keyword>
  <keyword>Antipsychotics</keyword>
  <keyword>Combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clozapine</mesh_term>
    <mesh_term>Amisulpride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

